Bristol-Myers Squibb (BMY) Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: Approximately $11.5 billion, up 1% year-over-year.

Growth Portfolio Sales: Increased 9% to $6.2 billion, driven by products like Reblozyl, Breyanzi, and Opdualag.

Eliquis Revenue: Approximately $4.1 billion, reflecting a 13% increase.

Opdivo Revenue: Decreased 8% to $2.1 billion, primarily due to inventory drawdowns.

Diluted Earnings Per Share: $1.58, including a net charge of $0.03 related to in-process R&D.

Gross Margin: Declined by 280 basis points to 70.3%.

Operating Cash Flow: Approximately $1.1 billion, impacted by lower net cash collections due to Eliquis price reductions.

2Strategic Updates and Business Highlights

R&D Focus: Continued emphasis on life-threatening diseases with a diversified pipeline. Key advancements include:

Iberdomide: FDA filing accepted for multiple myeloma with a PDUFA date of August 17.

Mezigdomide: Positive Phase III interim data for multiple myeloma.

Cobenfy: Steady growth in revenue and ongoing trials for Alzheimer's psychosis.

Life Cycle Management: Recent approvals for SOTYKTU in psoriatic arthritis and Opdivo for new indications.

Cost Savings Initiative: On track to deliver $2 billion in cost savings by the end of 2027.

3Forward Guidance and Outlook

Financial Guidance: Reaffirmed full-year 2026 guidance, with expectations tracking towards the upper end of revenue and EPS ranges.

Pivotal Readouts: Anticipated late 2026 readouts for key programs, including Milvexian and iberdomide, which are expected to enhance long-term growth prospects.

4Bad News, Challenges, or Points of Concern

Opdivo Decline: Notable revenue drop due to inventory adjustments and competition from Cobenfy.

Gross Margin Pressure: Decline attributed to product mix and increased generic competition.

Regulatory Risks: Upcoming pivotal readouts carry inherent risks, and any negative outcomes could impact future growth strategies.

Competitive Landscape: Increased competition in oncology and cardiovascular segments, particularly with new entrants and generics.

5Notable Q&A Insights

Clinical Readouts: Confidence expressed in upcoming readouts for iberdomide and Milvexian, with significant implications for business development strategies.

Cobenfy Trials: The decision to include biomarker-selected populations in trials aims to enhance the precision of patient recruitment and efficacy.

Market Dynamics: Discussion on the potential for Milvexian to address unmet needs in anticoagulation therapy, particularly regarding bleeding risks compared to existing treatments.

Cell Therapy Strategy: Emphasis on a multimodal approach in cell therapies, with ongoing trials in autoimmune diseases and a focus on scalability. Overall, BMY's Q1 2026 results reflect a solid performance amidst challenges, with a strong focus on innovation and strategic growth initiatives. The company remains optimistic about its pipeline and financial outlook, despite facing competitive pressures and regulatory risks.